checkAd
    Shanghai Junshi Biosciences Ltd Registered (H) Aktie
    1,4700
     
    EUR
    0,00 %
    0,0000 EUR
    Letzter Kurs 09:59:02 Frankfurt
    1,4200
     
    EUR
    1.409 STK
    Geldkurs 10:01:19
    1,5500
     
    EUR
    1.291 STK
    Briefkurs 10:00:04
    ISIN: CNE100003FF7 · WKN: A2N9PC · SYM: 8SJ · China

    Neueste Nachrichten

    Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
    25.04.24 · globenewswire · Shanghai Junshi Biosciences Ltd Registered (H)
    Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
    07.04.24 · globenewswire · Shanghai Junshi Biosciences Ltd Registered (H)
    Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
    29.03.24 · globenewswire · Shanghai Junshi Biosciences Ltd Registered (H)
    Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority
    02.02.24 · globenewswire · Shanghai Junshi Biosciences Ltd Registered (H)
    Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer
    18.01.24 · globenewswire · Shanghai Junshi Biosciences Ltd Registered (H)
    Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine
    10.01.24 · globenewswire · Shanghai Junshi Biosciences Ltd Registered (H)
    Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients
    02.01.24 · globenewswire · Shanghai Junshi Biosciences Ltd Registered (H)
    Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19
    23.11.23 · globenewswire · Shanghai Junshi Biosciences Ltd Registered (H)
    Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023
    27.10.23 · globenewswire · Shanghai Junshi Biosciences Ltd Registered (H)
    Junshi Biosciences Announces 2023 Interim Financial Results and Provides Corporate Updates
    31.08.23 · globenewswire · Shanghai Junshi Biosciences Ltd Registered (H)
    Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer
    20.07.23 · globenewswire · Shanghai Junshi Biosciences Ltd Registered (H)
    Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab
    12.07.23 · globenewswire · Shanghai Junshi Biosciences Ltd Registered (H)